Annexin A1 sustains tumor metabolism and cellular proliferation upon stable loss of HIF1A

Despite the approval of numerous molecular targeted drugs, long-term antiproliferative efficacy is rarely achieved and therapy resistance remains a central obstacle of cancer care. Combined inhibition of multiple cancer-driving pathways promises to improve antiproliferative efficacy. HIF-1 is a driv...

Descripción completa

Detalles Bibliográficos
Autores principales: Rohwer, Nadine, Bindel, Fabian, Grimm, Christina, Lin, Suling J., Wappler, Jessica, Klinger, Bertram, Blüthgen, Nils, Du Bois, Ilona, Schmeck, Bernd, Lehrach, Hans, de Graauw, Marjo, Goncalves, Emanuel, Saez-Rodriguez, Julio, Tan, Patrick, Grabsch, Heike I., Prigione, Alessandro, Kempa, Stefan, Cramer, Thorsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872743/
https://www.ncbi.nlm.nih.gov/pubmed/26760764
http://dx.doi.org/10.18632/oncotarget.6793

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872743/
https://www.ncbi.nlm.nih.gov/pubmed/26760764
http://dx.doi.org/10.18632/oncotarget.6793

Ejemplares similares